Synaptic Vesicle 2A (SV2A) Positron Emission Tomography (PET) Imaging as a Marker of Therapeutic Response in a Mouse Model of Depression

被引:0
|
作者
Corvo, Cassandre [1 ]
Mendez-David, Indira [2 ]
Goutal, Sebastien [1 ]
Saba, Wadad [1 ]
Bottlaender, Michel [1 ]
Caille, Fabien [1 ]
Hen, Rene [3 ,4 ]
Colle, Romain [2 ]
Corruble, Emmanuelle [2 ]
Tournier, Nicolas [1 ]
Leroy, Claire [1 ]
David, Denis J. [2 ]
机构
[1] Univ Paris Saclay, Serv Hosp Frederic Joliot, INSERM, CNRS,CEA,Lab Imagerie Biomed Multimodale BioMaps, F-91401 Orsay, France
[2] Univ Paris Saclay, Ctr Rech Epidemiol & Sante Populat CESP, Inserm, UMR 1018,Team Moods, F-91400 Orsay, France
[3] Columbia Univ, Dept Psychiat, New York, NY 10027 USA
[4] New York State Psychiat Inst & Hosp, Div Integrat Neurosci, New York, NY 10019 USA
关键词
Major depressive disorder; CORT model; Synapticdensity; Antidepressant; Positron emission tomography; NEUROGENESIS; FLUOXETINE; ANXIETY;
D O I
10.1021/acsptsci.4c00621
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this preclinical pilot study, we used [11C]UCB-J PET imaging to monitor the synaptic modulation in depression and after fluoxetine. PET imaging was performed in a validated mouse model of depression/anxiety (CORT model), and the effect of 5-week treatment with fluoxetine was tested. Depression/anxiety phenotype and antidepressant action of fluoxetine were confirmed using the novelty-suppressed feeding test, previously validated in the CORT model. PET data showed significant decreases of volume of distribution (V T) of [11C]UCB-J in most brain regions of CORT mice compared with controls after 5 weeks of fluoxetine, and a trend toward restoration of V T values to control levels was observed, although it reached significance only in the olfactory bulb. These preliminary data support the use of [11C]UCB-J PET imaging and the CORT model to study the synaptic modulation of antidepressants. It provides excellent translational opportunities to study the relationship between synaptic plasticity and the clinical efficacy of antidepressants.
引用
收藏
页码:339 / 345
页数:7
相关论文
共 50 条
  • [41] A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release
    Tokudome, Kentaro
    Okumura, Takahiro
    Terada, Ryo
    Shimizu, Saki
    Kunisawa, Naofumi
    Mashimo, Tomoji
    Serikawa, Tadao
    Sasa, Masashi
    Ohno, Yukihiro
    FRONTIERS IN PHARMACOLOGY, 2016, 7
  • [42] PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging
    Toyonaga, Takuya
    Fesharaki-Zadeh, Arman
    Strittmatter, Stephen M.
    Carson, Richard E.
    Cai, Zhengxin
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [43] Temporal and spatial changes in synaptic vesicle glycoprotein 2A (SV2A) under kainic acid induced epileptogenesis: An autoradiographic study
    Pazarlar, Burcu Azak
    Madsen, Clara A.
    Oyar, Eser Oz
    Egilmen, Cansu B.
    Mikkelsen, Jens D.
    EPILEPSY RESEARCH, 2022, 183
  • [44] Characteristics of ear fullness and synaptic loss in ear fullness revealed by SV2A positron emission tomographycortical
    Zhou, En
    Xiao, Xuping
    Liu, Bin
    Tan, Zhiqiang
    Zhong, Jiayu
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2024, 17
  • [45] GMP-compliant automated radiosynthesis of [18F] SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2 A (SV2A)
    Chen, Lijuan
    Li, Xiaochen
    Ge, Yao
    Li, Huiqiang
    Li, Ruili
    Song, Xiaosheng
    Liang, Jianfei
    Zhang, Weifeng
    Li, Xiaona
    Wang, Xiaoqi
    Wang, Yunjuan
    Wu, Yaping
    Bai, Yan
    Wang, Meiyun
    EJNMMI RADIOPHARMACY AND CHEMISTRY, 2024, 9 (01)
  • [46] Direct competition binding between a vesicle glycoprotein 2A (SV2A) PET ligand and a γ-secretase-modulator tool compound
    Kunze, Lea
    Wind, Karin
    Palumbo, Giovanna
    Bartenstein, Peter
    Ziegler, Sibylle
    Honer, Michael
    Sarmiento, Rosa Rodriguez
    Lindemann, Lothar
    Brendel, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [47] Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein
    Gillard, M
    Chatelain, P
    Fuks, B
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 536 (1-2) : 102 - 108
  • [48] Radiosynthesis of 11C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression
    Cai, Hancheng
    Mangner, Thomas J.
    Muzik, Otto
    Wang, Ming-Wei
    Chugani, Diane C.
    Chugani, Harry T.
    ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (10): : 1152 - 1155
  • [49] Synaptic Terminal Density Early in the Course of Schizophrenia: An In Vivo UCB-J Positron Emission Tomographic Imaging Study of SV2A
    Onwordi, Ellis Chika
    Whitehurst, Thomas
    Shatalina, Ekaterina
    Mansur, Ayla
    Arumuham, Atheeshaan
    Osugo, Martin
    Marques, Tiago Reis
    Jauhar, Sameer
    Gupta, Susham
    Mehrotra, Ravi
    Rabiner, Eugenii A.
    Gunn, Roger N.
    Natesan, Sridhar
    Howes, Oliver D.
    BIOLOGICAL PSYCHIATRY, 2024, 95 (07) : 639 - 646
  • [50] Increased Inflammation and Unchanged Density of Synaptic Vesicle Glycoprotein 2A (SV2A) in the Postmortem Frontal Cortex of Alzheimer's Disease Patients
    Metaxas, Athanasios
    Thygesen, Camilla
    Briting, Sanne R. R.
    Landau, Anne M.
    Darvesh, Sultan
    Finsen, Bente
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2019, 13